These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 24156974)

  • 41. Adverse drug reactions in patients with Alzheimer's disease and related dementia in France: a national multicentre cross-sectional study.
    Laroche ML; Perault-Pochat MC; Ingrand I; Merle L; Kreft-Jais C; Castot-Villepelet A; Durrieu G; Gras V; Guy C; Jean-Pastor MJ; Jonville-Béra AP; Merlet-Chicoine I; Miremont-Salamé G; Nourhashemi F; Charmes JP;
    Pharmacoepidemiol Drug Saf; 2013 Sep; 22(9):952-60. PubMed ID: 23794320
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Drug-induced panic attacks: Analysis of cases registered in the French pharmacovigilance database.
    Abadie D; Essilini A; Fulda V; Gouraud A; Yéléhé-Okouma M; Micallef J; Montastruc F; Montastruc JL
    J Psychiatr Res; 2017 Jul; 90():60-66. PubMed ID: 28231495
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A comparative study of adverse drug reactions during two heat waves that occurred in France in 2003 and 2006.
    Sommet A; Durrieu G; Lapeyre-Mestre M; Montastruc JL;
    Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):285-8. PubMed ID: 22162094
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Are non-serious adverse reactions to psychiatric drugs really non-serious?
    Pozzi M; Bertella S; Cattaneo D; Molteni M; Perrone V; Carnovale C; Antoniazzi S; Clementi E; Radice S
    J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):394-400. PubMed ID: 23952186
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Severe adverse drug reactions in psychiatric inpatients treated with neuroleptics.
    Bender S; Grohmann R; Engel RR; Degner D; Dittmann-Balcar A; Rüther E
    Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S46-53. PubMed ID: 15052514
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Hypothermia induced by neuroleptics. Clinical case report].
    Fanello S; Blay M; Lainé-Cessac P; Daryabin M
    Rev Med Interne; 2001 Aug; 22(8):764-6. PubMed ID: 11534367
    [No Abstract]   [Full Text] [Related]  

  • 47. Impact of the "French Levothyrox crisis" on signal detection in the World Health Organization pharmacovigilance database.
    Khouri C; Revol B; Lepelley M; Mallaret M; Cracowski JL
    Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1427-1428. PubMed ID: 30379373
    [No Abstract]   [Full Text] [Related]  

  • 48. Antipsychotic drug-induced hypoglycemia and hypothermia.
    Käräjämäki A; Lauri T; Ebeling T
    Duodecim; 2017; 133(3):301-4. PubMed ID: 29205832
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Neuroleptic malignant syndrome in users of risperidone].
    Gerritsen AA; de Jonghe-Rouleau AP; Stienstra-Liem LH
    Ned Tijdschr Geneeskd; 2004 Sep; 148(37):1801-4. PubMed ID: 15495506
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France.
    Olivier P; Montastruc JL
    Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):808-12. PubMed ID: 16700082
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adverse events reported for Mirena levonorgestrel-releasing intrauterine device in France and impact of media coverage.
    Langlade C; Gouverneur A; Bosco-Lévy P; Gouraud A; Pérault-Pochat MC; Béné J; Miremont-Salamé G; Pariente A;
    Br J Clin Pharmacol; 2019 Sep; 85(9):2126-2133. PubMed ID: 31218710
    [TBL] [Abstract][Full Text] [Related]  

  • 52. French pharmacovigilance: Missions, organization and perspectives.
    Vial T
    Therapie; 2016 Apr; 71(2):143-50. PubMed ID: 27080832
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions.
    Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antipsychotics and seizures: higher risk with atypicals?
    Lertxundi U; Hernandez R; Medrano J; Domingo-Echaburu S; García M; Aguirre C
    Seizure; 2013 Mar; 22(2):141-3. PubMed ID: 23146619
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hypothermia developing during neuroleptic treatment.
    Hamuro A; Miyaoka H; Iguchi T; Kamijima K
    Pharmacopsychiatry; 1999 Nov; 32(6):258-9. PubMed ID: 10599937
    [No Abstract]   [Full Text] [Related]  

  • 56. [Joint program of pharmacovigilance in Quebec: comparison with France, Aquitaine and the Basque region].
    Biron P; Balency D
    Therapie; 1996; 51(5):578-81. PubMed ID: 9138400
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Neuroleptic malignant syndrome--a case report on diagnosis, differential diagnosis and therapy of a life threatening complication of treatment with neuroleptics].
    Staud L; Pflug B
    Psychiatr Prax; 1992 Jul; 19(4):114-8. PubMed ID: 1354879
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Amisulpride and neuroleptic malignant syndrome.
    Tu MC; Hsiao CC
    Chang Gung Med J; 2011; 34(5):536-40. PubMed ID: 22035899
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Drug-induced hyperprolactinemia: a case-non-case study from the national pharmacovigilance database].
    Petit A; Piednoir D; Germain ML; Trenque T
    Therapie; 2003; 58(2):159-63. PubMed ID: 12942857
    [TBL] [Abstract][Full Text] [Related]  

  • 60. French Pharmacovigilance Public System and COVID-19 Pandemic.
    Grandvuillemin A; Drici MD; Jonville-Bera AP; Micallef J; Montastruc JL;
    Drug Saf; 2021 Apr; 44(4):405-408. PubMed ID: 33372244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.